Yamamoto Yuji, Tomioka Yasufumi, Numa Kohsaku, Tanaka Hiroshi, Imai Kojiro, Ueno Morio, Sotozono Chie, Kinoshita Shigeru
Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto, 602-8566, Japan.
Department for Medical Innovation and Translational Medical Science, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Jpn J Ophthalmol. 2025 Sep 15. doi: 10.1007/s10384-025-01280-6.
Using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), to evaluate vision-related quality of life outcomes in patients with bullous keratopathy after cultured corneal endothelial cell (CEC) transplant.
Single-center prospective clinical trial METHODS: In this prospective, single-center study, 11 consecutive patients with bullous keratopathy underwent cultured CEC transplant. The NEI VFQ-25 was administered through in-person interviews by trained interviewers at baseline and at 24 weeks postoperatively. The NEI VFQ-25 comprises 12 subscales that assess different aspects of vision-related quality of life. Changes in composite and subscale scores were analyzed.
The patients comprised 5 men and 6 women, with a mean age of 64.4 years (range 49-82 years). All the patients had pseudophakic bullous keratopathy, with Fuchs endothelial corneal dystrophy being the predominant underlying cause of disease (7 eyes). The NEI VFQ-25 composite score improved significantly from 61.8 ± 11.9 to 79.5 ± 8.0 (P <.01). Significant improvements were observed in general vision, ocular pain, near vision, social function, mental health, role limitations, dependency, and peripheral vision subscales (P <.05). General health, distance vision, driving, and color vision subscales showed minimal improvement.
Cultured CEC transplant significantly improved vision-related quality of life in patients with bullous keratopathy. The comprehensive improvement across multiple NEI VFQ-25 domains suggests that this novel therapeutic approach may be a viable treatment option for corneal endothelial dysfunction.
使用美国国立眼科研究所视觉功能问卷25项（NEI VFQ - 25）评估培养角膜内皮细胞（CEC）移植术后大泡性角膜病变患者的视力相关生活质量结果。
单中心前瞻性临床试验
在这项前瞻性单中心研究中，11例连续性大泡性角膜病变患者接受了培养的CEC移植。NEI VFQ - 25由经过培训的访员在基线和术后24周通过面对面访谈进行施测。NEI VFQ - 25包含12个分量表，用于评估视力相关生活质量的不同方面。分析了综合得分和分量表得分的变化。
患者包括5名男性和6名女性，平均年龄64.4岁（范围49 - 82岁）。所有患者均为人工晶状体眼大泡性角膜病变，其中Fuchs内皮角膜营养不良是主要的潜在病因（7只眼）。NEI VFQ - 25综合得分从61.8±11.9显著提高至79.5±8.0（P<.01）。在总体视力、眼痛、近视力、社会功能、心理健康、角色限制、依赖和周边视力分量表中观察到显著改善（P<.05）。总体健康、远视力、驾驶和色觉分量表改善最小。
培养的CEC移植显著改善了大泡性角膜病变患者的视力相关生活质量。NEI VFQ - 25多个领域的全面改善表明，这种新的治疗方法可能是角膜内皮功能障碍的一种可行治疗选择。
